Always Smile With Daewoong

home Home > About Us > Recruitment > News

뉴스
No	Subject	Data
283	A global symposium pays attention to Nav 1.7 Chronic Pain Treatment, DWP17061.	2019-06-25
282	Daewoong Pharmaceutical’s ‘Nabota’ secured application to blepharospasm.	2019-06-24
281	Daewoong Pharmaceutical initiates development of new medication for hearing impairment (First in Class) with Yonsei University based on the ion channel platform technology.	2019-06-13
280	Daewoong Pharmaceutical’s diabetes treatment, ‘DWP16001,’ approved for clinical test phase 2 in Korea.	2019-05-31
279	Daewoong Pharmaceutical’s ‘Urusa 300mg’ secured application to ‘prevention of gallbladder stones after gastrectomy’ for the first time in the world.	2019-05-29
278	Daewoong Pharmaceutical’s Botulinum Toxin officially released in the U.S... targeting the world’s largest Botulinum Toxin market.	2019-05-16
277	Daewoong Pharmaceutical has released ‘Olomax’ for both hypertension and hyperlipidemia	2019-05-03
276	Daewoong Pharmaceutical hosted a symposium titled ‘NABOTA Sparkling Night’ in Thailand	2019-05-03
275	Daewoong Pharmaceutical’s botulinum toxin about to be released in Europe with European CHMP’s recommendation for approval	2019-04-26
274	Daewoong Pharmaceutical announced the excellence of Nabota through an overseas specialist training program.	2019-04-15

1 / 2 / 3 / 4 / 5 / 6 / 7 / 8 / 9 / 10 /